Sp1-Dependent Regulation of the RTP801 Promoter and Its Application to Hypoxia-Inducible VEGF Plasmid for Ischemic Disease
- 133 Downloads
Purpose. Gene therapy using vascular endothelial growth factor (VEGF) is a new potential treatment of ischemic disease. To be safe and effective, VEGF expression should be enhanced locally in ischemic tissue. In this study, we identified the cis-regulatory element for the hypoxia induction of the RTP801 promoter. In addition, pRTP801-VEGF was evaluated as a therapeutic plasmid in vitro.
Methods. The cis-regulatory element for hypoxia induction was identified by deletion and mutation analyses. Antisense oligonucleotide co-transfection assay was performed to evaluate the role of Sp1. pRTP801-VEGF was constructed by the insertion of the RTP801 promoter into the VEGF plasmid. The hypoxia-inducible expression of VEGF was evaluated by in vitro transfection assay.
Results. In luciferase assay, the region between -495 and -446 was responsible for the hypoxia-induced transcription. The mutation of the Sp1 site in this region reduced hypoxia-induced transcription. In addition, co-transfection with antisense Sp1 oligonucleotide suggests that hypoxia induction of the RTP801 promoter is mediated by Sp1. In vitro transfection showed that pRTP801-VEGF had higher VEGF expression than pEpo-SV-VEGF. In addition, VEGF expression by pRTP801-VEGF was induced under hypoxia.
Conclusions. With strong basal promoter activity and induction under hypoxia, pRTP801-VEGF may be useful for gene therapy for ischemic disease.
Unable to display preview. Download preview PDF.
- 1.M. Azrin. Angiogenesis, protein and gene delivery. Br. Med. Bull. 59:211-215 (2001).Google Scholar
- 2.J. Kastrup, E. Jorgensen, and V. Drvota. Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium. Therapeutic angiogenesis. Scand. Cardiovasc. J. 35:291-296 (2001).Google Scholar
- 3.J. M. Isner. Myocardial gene therapy. Nature 415:234-239 (2002).Google Scholar
- 4.J. F. Symes, D. W. Losordo, P. R. Vale, K. G. Lathi, D. D. Esakof, M. Mayskiy, and J. M. Isner. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68:836-837 (1999).Google Scholar
- 5.P. R. Vale, D. W. Losordo, C. E. Milliken, M. Maysky, D. D. Esakof, J. F. Symes, and J. M. Isner. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102:965-974 (2000).Google Scholar
- 6.C. Sylven, N. Sarkar, A. Ruck, V. Drvota, S. Y. Hassan, B. Lind, A. Nygren, Q Kallner, P. Blomberg, J. van der Lindern, D. Lindblom, L. A. Brodin, and K. B. Islam. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron. Artery Dis. 12:239-243 (2001).Google Scholar
- 7.D. G. Affleck, L. Yu, D. A. Bull, S. H. Bailey, and S. W. Kim. Augmentation of myocardial transfection using TerplexDNA: a novel gene delivery system. Gene Ther. 8:349-353 (2001).Google Scholar
- 8.M. Lee, J. Rentz, S. Han, D. A. Bull, and S. W. Kim. Water soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther. 10:585-593 (2003).Google Scholar
- 9.E. Brogi, G. Schatteman, T. Wu, E. A. Kim, L. Varticovski, B. Keyt, and J. M. Isner. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Invest. 97:469-476 (1996).Google Scholar
- 10.J. S. Lee and A. M. Feldman. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nature Med. 4:739-742 (1998).Google Scholar
- 11.M. L. Springer, A. S. Chen, P. E. Kraft, M. Bednarski, and H. M. Blau. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2:549-558 (1998).Google Scholar
- 12.R. J. Lee, M. L. Springer, W. E. Blanco-Bose, R. Shaw, P. C. Ursell, and H. M. Blau. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102:898-901 (2000).Google Scholar
- 13.M. Lee, J. Rentz, M. Bikram, S. Han, D. A. Bull, and S. W. Kim. Hypoxia inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther. 10:1535-1542 (2003).Google Scholar
- 14.H. Su, J. Arakawa-Hoyt, and Y. W. Kan. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. USA 99:9480-9485 (2002).Google Scholar
- 15.T. Shoshani, A. Faerman, I. Mett, E. Zelin, T. Tenne, S. Corodin, Y. Moshel, S. Elbaz, A. Budanov, A. Chajut, H. Kalinski, I. Kamer, A. Rozen, O. Mor, E. Keshet, D. Leshkowitz, P. Einat, R. Skaliter, and E. Feinstein. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22:2283-2293 (2002).Google Scholar
- 16.G. L. Wang, B.-H. Jiang, E. Rue, and G. L. Semenza. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92:5510-5514 (1995).Google Scholar
- 17.R. H. Wenger and M. Gassmann. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378:609-616 (1997).Google Scholar
- 18.B.-H. Jiang, E. Rue, G. L. Wang, R. Roe, and G. L. Semenza. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271:17771-17778 (1996).Google Scholar
- 19.G. L. Semenza, B. H. Jiang, S. W. Leung, R. Passantino, J. P. Concordet, P. Maire, and A. Giallongo. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271:32529-32537 (1996).Google Scholar
- 20.G. L. Wang and G. L. Semenza. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90:4304-4308 (1993).Google Scholar
- 21.Q. Xu, Y.-S. Ji, and J. F. Schmedtje Jr. Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. J. Biol. Chem. 275:24583-24589 (2000).Google Scholar
- 22.L. E. Huang, J. Gu, M. Schau, and H. F. Bunn. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95:7987-7992 (1998).Google Scholar
- 23.T. Sanchez-Elsner, L. M. Botella, B. Velasco, C. Langa, and C. Bernabeu. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth pathways. J. Biol. Chem. 277:43799-43808 (2002).Google Scholar